- Home
- BEAT vs BRNS Comparison
BEAT vs BRNS Comparison
Compare BEAT & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BEAT | BRNS |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.7M | 24.1M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BEAT | BRNS |
|---|---|---|
| Price | $0.50 | $0.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $5.63 | $4.00 |
| AVG Volume (30 Days) | ★ 397.6K | 30.7K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.07 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $315.97 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.47 | $0.51 |
| 52 Week High | $4.00 | $1.83 |
Technical Indicators
Market Signals| Indicator | BEAT | BRNS |
|---|---|---|
| Relative Strength Index (RSI) | 39.50 | N/A |
| Support Level | N/A | N/A |
| Resistance Level | $0.63 | N/A |
| Average True Range (ATR) | 0.03 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 7.78 | 0.00 |
Price Performance
Historical ComparisonAbout BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company focused on developing higher resolution ambulatory electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The company's proprietary and patented technology platform captures the heart's electrical activity from three dimensions and synthesizes a 12-lead ECG from these signals. The company has received U.S. Food and Drug Administration (FDA) clearance for its ECG solutions.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.